Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age

Clin Infect Dis. 2021 Mar 15;72(6):1059-1063. doi: 10.1093/cid/ciaa861.

Abstract

No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.

Keywords: HIV infection; bisphosphonates; bone; children.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Alendronate / adverse effects
  • Bone Density
  • Bone Density Conservation Agents*
  • Bone Diseases, Metabolic*
  • Child
  • Cross-Over Studies
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans

Substances

  • Bone Density Conservation Agents
  • Alendronate